Search results
Results from the WOW.Com Content Network
Upon achieving appropriate control over eosinophilia, the medication can be gradually reduced. [25] Steroid-refractory HES has been managed with a variety of cytotoxic treatments. [24] Out of all of them, hydroxyurea has been researched the most and has been linked to few side effects at doses as high as 2 g per day. [26]
Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5 × 10 8 /L (500/μL). [1] Hypereosinophilia is an elevation in an individual's circulating blood eosinophil count above 1.5 × 10 9 /L (i.e. 1,500/μL).
Eosinophils play a central role in defending the body against infection by parasites. Many diseases, such as asthma and eczema, are caused when eosinophils overreact to environmental triggers and release an excess of chemicals, e.g., cytokines and histamine. The common characteristic among different causes of eosinophilic pneumonia is ...
For instance, patients with eosinophilic asthma have high levels of eosinophils that lead to inflammation and tissue damage, making it more difficult for patients to breathe. [6] [7] Eosinophils persist in the circulation for 8–12 hours, and can survive in tissue for an additional 8–12 days in the absence of stimulation. [8]
The symptoms of DRESS syndrome usually begin 2 to 6 weeks but uncommonly up to 8–16 weeks after exposure to an offending drug. Symptoms generally include fever, an often itchy rash which may be morbilliform or consist mainly of macules or plaques, facial edema (i.e. swelling, which is a hallmark of the disease), enlarged and sometimes painful lymph nodes, and other symptoms due to ...
Diagnosis is based on a skin biopsy and involvement of more than 30% of the skin. [3] TEN is a type of severe cutaneous adverse reactions (SCARs), together with SJS, a SJS/TEN, and drug reaction with eosinophilia and systemic symptoms. [5] It is called SJS when less than 10% of the skin is involved and an intermediate form with 10 to 30% ...
Clonal hypereosinophilia, also termed primary hypereosinophilia or clonal eosinophilia, is a grouping of hematological disorders all of which are characterized by the development and growth of a pre-malignant or malignant population of eosinophils, a type of white blood cell that occupies the bone marrow, blood, and other tissues.
No universal treatment guidelines have been established for tropical pulmonary eosinophilia. [3] The antifilarial diethylcarbamazine (6 mg/kg/day in three divided doses [2] for 21 days [8] remains the main therapeutic agent, and is generally well tolerated. Reported side effects include headache, fever, pruritus and gastrointestinal upset. [14]